April 24th 2024
In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Says Targeted Biopsy with MRI Reduces Overdiagnosis of Prostate Cancer by Half
December 12th 2022In a study of nearly 18,000 men who had prostate cancer screening, researchers found the use of pre-biopsy magnetic resonance imaging (MRI) for those with elevated prostate-specific antigen (PSA) levels and reserving MRI-targeted biopsy for those with PI-RADS scores of 3 to 5 reduced the risk of detecting clinically insignificant cancers by half.
Could an Emerging AI Platform Supplant Traditional MRI for Assessing Prostate Cancer?
December 7th 2022The Food and Drug Administration has granted 510(k) clearance to iQuest (Avenda Health), an artificial intelligence (AI) platform that combines findings from magnetic resonance imaging (MRI), pathology reports and biopsy results to facilitate three-dimensional mapping of prostate cancer.
Study Assesses PET Agent for Detecting Pelvic Lymph Node Metastases in Patients with Prostate Cancer
December 6th 2022For patients recently diagnosed with prostate cancer, the emerging positron emission tomography (PET) agent 18F-rhPSMA-7.3 reportedly has a 96 percent specificity rate for detecting pelvic lymph node metastases, according to Phase 3 study results recently presented at the 22nd Annual Scientific Meeting of the Society of Urologic Oncology (SUO).
Can MRI-Based Prostate Cancer Screening be a Viable Alternative to PSA Testing?
December 1st 2022In what may be the first study to assess the effectiveness of biparametric magnetic resonance imaging (MRI) for prostate cancer screening in a large cohort, researchers found that MRI screening had a significantly lower false positive rate and significantly higher positive predictive values (PPVs) than prostate-specific antigen (PSA)-based screening.
Radiotherapy for Prostate Cancer: Study Says MRI Guidance Significantly Reduces GU and GI Toxicities
October 28th 2022For patients undergoing stereotactic body radiotherapy (SBRT) for prostate cancer, the acute genitourinary (GU) toxicity rate associated with the procedure was 19 percent lower with magnetic resonance imaging (MRI) guidance in comparison to computed tomography (CT) guidance, according to new research presented recently at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Study Suggests Shorter Duration of Radiation Therapy is Effective for High-Risk Prostate Cancer
October 24th 2022Five weeks of radiation therapy is just as effective as eight weeks of radiation treatment for men with high-risk prostate cancer, according to new research presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Could a New PSMA-Derived Radiomics Model Help Detect Intraprostatic Lesions on PET/CT?
October 13th 2022An emerging radiomics model, derived from 68Ga-PSMA-11 PET, reportedly offers a superior area under the curve (AUC) and higher sensitivity than radiologist assessment in detecting intraprostatic lesions via positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer.
FDA to Review Blue Earth Diagnostics' Emerging PSMA/PET Agent for Prostate Cancer
September 27th 2022One prospective multicenter study found the radiohybrid prostate-specific membrane antigen (PSMA) agent 18F-rhPSMA-7.3 had an 83 percent detection rate in nearly 400 men with suspected prostate cancer.
Study Shows Adjunctive Benefit of Pre-Biopsy MRI for Diagnosing Prostate Cancer
September 20th 2022Emerging research suggests that combining pre-biopsy magnetic resonance imaging (MRI) with prostate-specific antigen (PSA) testing more than triples the specificity rate for detecting clinically significant prostate cancer in comparison to sole reliance on a PSA level greater than or equal to 4 ng/mL.
FDA Clears New AI Software for MRI Detection of Prostate Cancer
August 8th 2022The ProstatID, an adjunctive artificial intelligence software that radiologists can utilize with traditional magnetic resonance imaging (MRI), reportedly measures prostate gland volume, and suggests PI-RADS scoring of suspicious lesions.
Study Finds Key Benefits and Low Use of Pre-Op MRI for Patients Having Surgery for Prostate Cancer
June 17th 2022Despite increased use of preoperative magnetic resonance imaging (MRI) in recent years for patients undergoing surgery for prostate cancer, a study found that over 70 percent of a large Medicare population with prostate cancer did not have a preoperative MRI scan as of 2015.